BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+3.33%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$7.83B
AUM Growth
+$7.83B
(-1.8%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
2%
Top 10 Holdings %
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
12
Closed
5
Top Buys
| 1 |
Insmed
INSM
|
$217M |
| 2 |
Summit Therapeutics
SMMT
|
$181M |
| 3 |
Alkermes
ALKS
|
$101M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$90.2M |
| 5 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$20.8M |
Top Sells
| 1 |
Incyte
INCY
|
$330M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$62.1M |
| 3 |
Roivant Sciences
ROIV
|
$48.8M |
| 4 |
Akero Therapeutics
AKRO
|
$37.9M |
| 5 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$37.5M |
Sector Composition
| 1 | Healthcare | 98.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Incyte
INCY
$16.5B
| $1.86B | 23.81% | 30,738,524 -5,441,141 | -15% | -$330M |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.51B | 19.27% | 10,568,897 | – | – |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $697M | 8.9% | 42,877,916 +13,304 | +0% | +$216K |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $553M | 7.07% | 1,974,590 +4,792 | +0.2% | +$1.34M |
|
5
Revolution Medicines
RVMD
$7.1B
| $294M | 3.75% | 7,569,090 +19,841 | +0.3% | +$770K |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $263M | 3.36% | 6,398,365 | – | – |
|
|
7
Insmed
INSM
$28.8B
| $240M | 3.06% | 3,576,038 +3,233,038 | +943% | +$217M |
|
|
BCYC
8
Bicycle Therapeutics
BCYC
$511M
| $190M | 2.43% | 9,399,960 +4,457,137 | +90% | +$90.2M |
|
|
9
Summit Therapeutics
SMMT
$17.6B
| $181M | 2.31% | +23,222,222 | New | +$181M |
|
10
Kymera Therapeutics
KYMR
$2.95B
| $179M | 2.29% | 5,995,928 | – | – |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $105M | 1.34% | 5,840,059 | – | – |
|
|
12
Alkermes
ALKS
$4.78B
| $101M | 1.29% | +4,181,751 | New | +$101M |
|
13
Replimune Group
REPL
$422M
| $90.4M | 1.16% | 10,045,336 +500,000 | +5% | +$4.5M |
|
14
Denali Therapeutics
DNLI
$2.23B
| $86.6M | 1.11% | 3,731,695 | – | – |
|
15
AbCellera Biologics
ABCL
$1.25B
| $81.5M | 1.04% | 27,525,640 | – | – |
|
16
Nurix Therapeutics
NRIX
$714M
| $81M | 1.04% | 3,882,125 | – | – |
|
17
Immatics
IMTX
$619M
| $74.9M | 0.96% | 6,443,398 | – | – |
|
18
Entrada Therapeutics
TRDA
$208M
| $69.3M | 0.89% | 4,865,819 | – | – |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $60.3M | 0.77% | 1,466,547 | – | – |
|
20
Stoke Therapeutics
STOK
$1.08B
| $59M | 0.75% | 4,368,443 +1,000,000 | +30% | +$13.5M |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $52.6M | 0.67% | 2,818,323 +8,746 | +0.3% | +$163K |
|
22
Immunocore
IMCR
$1.62B
| $51.4M | 0.66% | 1,515,318 | – | – |
|
23
argenx
ARGX
$43.6B
| $48.1M | 0.62% | 111,904 -39,311 | -26% | -$16.9M |
|
24
Kodiak Sciences
KOD
$478M
| $40.7M | 0.52% | 17,310,490 | – | – |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $38.7M | 0.5% | 993,679 | – | – |
|